2024 medtech predicted to stabilise growth above prepandemic average, focus on profitability and cash flow, continue pace in technological innovation, experience fluctuating growth across geographies, see gen AI adopters gain productivity benefits, maintain M&A deal volumes, and perceive minimal impact on industry growth by GLP-1 drugs. Insights inspired by dialogues with 200 leaders and McKinsey's decade-front medtech research.
